121 related articles for article (PubMed ID: 8431554)
1. Glycosylation of human IgG subclass and mouse IgG2b heavy chains secreted by mouse J558L transfectoma cell lines as chimeric antibodies.
Lund J; Takahashi N; Hindley S; Tyler R; Goodall M; Jefferis R
Hum Antibodies Hybridomas; 1993 Jan; 4(1):20-5. PubMed ID: 8431554
[TBL] [Abstract][Full Text] [Related]
2. Control of IgG/Fc glycosylation: a comparison of oligosaccharides from chimeric human/mouse and mouse subclass immunoglobulin Gs.
Lund J; Takahashi N; Nakagawa H; Goodall M; Bentley T; Hindley SA; Tyler R; Jefferis R
Mol Immunol; 1993 Jun; 30(8):741-8. PubMed ID: 8502242
[TBL] [Abstract][Full Text] [Related]
3. Studies of aglycosylated chimeric mouse-human IgG. Role of carbohydrate in the structure and effector functions mediated by the human IgG constant region.
Tao MH; Morrison SL
J Immunol; 1989 Oct; 143(8):2595-601. PubMed ID: 2507634
[TBL] [Abstract][Full Text] [Related]
4. Effect of C2-associated carbohydrate structure on Ig effector function: studies with chimeric mouse-human IgG1 antibodies in glycosylation mutants of Chinese hamster ovary cells.
Wright A; Morrison SL
J Immunol; 1998 Apr; 160(7):3393-402. PubMed ID: 9531299
[TBL] [Abstract][Full Text] [Related]
5. Multiple interactions of IgG with its core oligosaccharide can modulate recognition by complement and human Fc gamma receptor I and influence the synthesis of its oligosaccharide chains.
Lund J; Takahashi N; Pound JD; Goodall M; Jefferis R
J Immunol; 1996 Dec; 157(11):4963-9. PubMed ID: 8943402
[TBL] [Abstract][Full Text] [Related]
6. Production and molecular characterization of clinical phase i anti-melanoma mouse IgG3 monoclonal antibody R24.
Kemminer SE; Conradt HS; Nimtz M; Sagi D; Peter-Katalinić J; Diekmann O; Drmić I; Müthing J
Biotechnol Prog; 2001; 17(5):809-21. PubMed ID: 11587568
[TBL] [Abstract][Full Text] [Related]
7. Effects of buffering conditions and culture pH on production rates and glycosylation of clinical phase I anti-melanoma mouse IgG3 monoclonal antibody R24.
Müthing J; Kemminer SE; Conradt HS; Sagi D; Nimtz M; Kärst U; Peter-Katalinić J
Biotechnol Bioeng; 2003 Aug; 83(3):321-34. PubMed ID: 12783488
[TBL] [Abstract][Full Text] [Related]
8. Recombinant human-mouse chimeric monoclonal antibody specific for common acute lymphocytic leukemia antigen.
Nishimura Y; Yokoyama M; Araki K; Ueda R; Kudo A; Watanabe T
Cancer Res; 1987 Feb; 47(4):999-1005. PubMed ID: 2948638
[TBL] [Abstract][Full Text] [Related]
9. Glycosylation of IgG, immune complexes and IgG subclasses in the MRL-lpr/lpr mouse model of rheumatoid arthritis.
Bond A; Cooke A; Hay FC
Eur J Immunol; 1990 Oct; 20(10):2229-33. PubMed ID: 2242757
[TBL] [Abstract][Full Text] [Related]
10. Humanization of an anti-human IL-6 mouse monoclonal antibody glycosylated in its heavy chain variable region.
Sato K; Ohtomo T; Hirata Y; Saito H; Matsuura T; Akimoto T; Akamatsu K; Koishihara Y; Ohsugi Y; Tsuchiya M
Hum Antibodies Hybridomas; 1996; 7(4):175-83. PubMed ID: 9140729
[TBL] [Abstract][Full Text] [Related]
11. Modulation of therapeutic antibody effector functions by glycosylation engineering: influence of Golgi enzyme localization domain and co-expression of heterologous beta1, 4-N-acetylglucosaminyltransferase III and Golgi alpha-mannosidase II.
Ferrara C; Brünker P; Suter T; Moser S; Püntener U; Umaña P
Biotechnol Bioeng; 2006 Apr; 93(5):851-61. PubMed ID: 16435400
[TBL] [Abstract][Full Text] [Related]
12. In vitro galactosylation of human IgG at 1 kg scale using recombinant galactosyltransferase.
Warnock D; Bai X; Autote K; Gonzales J; Kinealy K; Yan B; Qian J; Stevenson T; Zopf D; Bayer RJ
Biotechnol Bioeng; 2005 Dec; 92(7):831-42. PubMed ID: 16187338
[TBL] [Abstract][Full Text] [Related]
13. Glycan analysis of monoclonal antibodies secreted in deposition disorders indicates that subsets of plasma cells differentially process IgG glycans.
Omtvedt LA; Royle L; Husby G; Sletten K; Radcliffe CM; Harvey DJ; Dwek RA; Rudd PM
Arthritis Rheum; 2006 Nov; 54(11):3433-40. PubMed ID: 17075835
[TBL] [Abstract][Full Text] [Related]
14. Chimeric human-mouse IgG antibodies with shuffled constant region exons demonstrate that multiple domains contribute to in vivo half-life.
Zuckier LS; Chang CJ; Scharff MD; Morrison SL
Cancer Res; 1998 Sep; 58(17):3905-8. PubMed ID: 9731501
[TBL] [Abstract][Full Text] [Related]
15. Comparisons of the glycosylation of a monoclonal antibody produced under nominally identical cell culture conditions in two different bioreactors.
Kunkel JP; Jan DC; Butler M; Jamieson JC
Biotechnol Prog; 2000; 16(3):462-70. PubMed ID: 10835250
[TBL] [Abstract][Full Text] [Related]
16. [Construction of expression vector for human-mouse chimeric antibody and expression of an antibody against human HER2].
Wang LL; Han H
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2004 May; 20(3):363-5. PubMed ID: 15193240
[TBL] [Abstract][Full Text] [Related]
17. cDNA cloning and sequencing of a novel monoclonal antibody to carcinoembryonic antigen and construction of a mouse/human chimeric antibody.
Shibaguchi H; Arakawa F; Imakiire T; Kuroki M; Kuroki M
Anticancer Res; 2003; 23(6a):4383-8. PubMed ID: 14666725
[TBL] [Abstract][Full Text] [Related]
18. The critical role of arginine residues in the binding of human monoclonal antibodies to cardiolipin.
Giles I; Lambrianides N; Latchman D; Chen P; Chukwuocha R; Isenberg D; Rahman A
Arthritis Res Ther; 2005; 7(1):R47-56. PubMed ID: 15642142
[TBL] [Abstract][Full Text] [Related]
19. Variations in oligosaccharide-protein interactions in immunoglobulin G determine the site-specific glycosylation profiles and modulate the dynamic motion of the Fc oligosaccharides.
Wormald MR; Rudd PM; Harvey DJ; Chang SC; Scragg IG; Dwek RA
Biochemistry; 1997 Feb; 36(6):1370-80. PubMed ID: 9063885
[TBL] [Abstract][Full Text] [Related]
20. Variable domain-linked oligosaccharides of a human monoclonal IgG: structure and influence on antigen binding.
Leibiger H; Wüstner D; Stigler RD; Marx U
Biochem J; 1999 Mar; 338 ( Pt 2)(Pt 2):529-38. PubMed ID: 10024532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
